Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder

Plymouth Meeting, Pa. —May 28, 2018 — Braeburn announces the resubmission of the New Drug Application (NDA) for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly depot injection for the treatment of opioid use disorder...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news